Don't Listen To The Naysayers-STXS Has Begun Its Forward Climb From A Revenue And Operational Perspective
STXS once 2013 is put to bed will show excellent forward progress from the standpoints of revenue and operations gains and these quarterly advances will stimulate investors into a buying action which will force share values ever higher. We have already seen the start of that process given the results for the Q3/2012 period. Folks, its all going to boil down to comparisons with last years performance levels. The STXS naysayers at this chatboard will lead you astray. There game here is history, They are just not willing to admit it. Don't pay any attention to them. STXS will be one of the best performing stocks in the med-tech equipment field during 2013. CEO Mike Kaminksy and his fine team have turned the corner given adjustments to their product offering and we are now going to see the fruits of that very big effort. STXS is a very strong buy and that was re-enforced through today's annoucement by Sphrosyne Capital that they have acquired a 5.1% stake in the company.